Clinical trial · Interventional
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Efficacy of PD-1-inhibitor-based Combination Therapy in Patients With Metastatic Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combinations | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Combination treatment
- description
- PD-1 inhibitor-based combination treatment
- interventionNames
- Drug: Combinations
Primary outcomes (1)
- measure
- Durable clinical benefit
- timeFrame
- immediately after the intervention
- description
- Rate of patients who acheived CR or PR or SD that lasted more than 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment * patients with identified genomic status Exclusion Criteria: * patients who received immune monotherapy * patients who stopped treatment for any reason without identified response assessment.
References
Publications (0)
Data not yet available